Inicio/Acciones/AIM

AIM

USD

AIM ImmunoTech Inc. Common Stock

$1.600-0.400 (-20.000%)

Precio en Tiempo Real

Healthcare

Biotecnología

Estados Unidos

Gráfico de Precios

Loading Chart...

Métricas Clave

Métricas de Mercado

Fundamentos de la Empresa

Estadísticas de Negociación

Métricas de Mercado

Apertura

$2.000

Máximo

$2.020

Mínimo

$1.570

Volumen

0.10M

Fundamentos de la Empresa

Capitalización de Mercado

4.4M

Industria

Biotecnología

País

United States

Estadísticas de Negociación

Volumen Promedio

0.10M

Bolsa

ASE

Moneda

USD

Rango de 52 Semanas

Mínimo $1.57Actual $1.600Máximo $36

Noticias Relacionadas

4 nov 2025 · 14:05

GlobeNewswire

AIM ImmunoTech Announces Late Breaking Abstract from University of Pittsburgh Medical Center Accepted for Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting

OCALA, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced that data from the completed Phase 2 cisplatin-resistant advanced recurrent ovarian cancer clinical

AIM ImmunoTech Announces Late Breaking Abstract from University of Pittsburgh Medical Center Accepted for Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting

3 nov 2025 · 13:55

GlobeNewswire

AIM ImmunoTech Announces European Patent Office Grants Patent Covering Ampligen® (Rintatolimod) for Use in the Treatment of the Post-COVID Condition of Fatigue

OCALA, Fla., Nov. 03, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced that the European Patent Office has officially granted AIM's European Patent No. 4,096,675, titled